Adaptin Bio (APTN) Cash from Operations (2023 - 2026)

Adaptin Bio's Cash from Operations history runs 4 years deep, the most recent figure standing at 596298.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 73.85% year-over-year to 596298.0; the TTM figure through Mar 2026 stood at 3094314.0 (down 8.98% YoY), while the FY2025 annual figure was 4777892.0, down 635.87% from the prior year.
• Cash from Operations came in at 596298.0 for Q1 2026 at Adaptin Bio, up from 702876.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 112653.0 in Q4 2024 to a low of 2279876.0 in Q1 2025.
• A 4-year average of 608182.0 and a median of 532357.0 in 2024 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations soared 293.07% in 2024 and slumped 2441.81% in 2025, its largest moves.
• Adaptin Bio's Cash from Operations stood at 58347.0 in 2023, then jumped by 293.07% to 112653.0 in 2024, then tumbled by 723.93% to 702876.0 in 2025, then rose by 15.16% to 596298.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 596298.0, 702876.0, and 772430.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison